research compound raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-10-26. Anything still debated is marked as such rather than presented as settled.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine in major jurisdictions | Sold as a research chemical; legal status varies |
| Anti-doping status | Prohibited by the World Anti-Doping Agency | Listed under non-approved substances or related category |
| Typical analytical method | LC-MS/MS | Used for detection and confirmation in biological samples |
| Storage temperature | −20 °C or lower for solid | Desiccated and protected from light |
| Common solution solvents | DMSO; ethanol | Aqueous solubility is limited |
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
Proteoglycans - Including chondroitin sulfate and heparan sulfate, which bind to collagen and may regulate collagen fibril diameters and play a role in mineralization Osteocalcin - A bone-specific protein involved in binding calcium during the mineralization process Osteonectin - May serve a bridging function between collagen and the mineral component Bone sialoprotein - Proteins rich in sialic acid that participate in matrix organization Growth factors - Including transforming growth factors, fibroblast growth factors, and insulin-like growth factors
MacKinnon, Charlotte M.; Carter, Philip E.; Smyth, S. Jane; Dunbar, Bryan; Fothergill, John E. (1987). "Molecular cloning of cDNA for human complement component C1s. The complete amino acid sequence". European Journal of Biochemistry. 169 (3): 547–553. doi:10.1111/j.1432-1033.1987.tb13644.x. PMID 3500856. Snoke, JE; Yanari, S; Bloch, K (1953). "Synthesis of glutathione from gamma-glutamylcysteine". The Journal of Biological Chemistry. 201 (2): 573–586. doi:10.1016/S0021-9258(18)66212-X. PMID 13061393. Mandeles, S; Block, K (1955). "Enzymatic synthesis of gamma-glutamylcysteine". The Journal of Biological Chemistry. 214 (2): 639–646. doi:10.1016/S0021-9258(18)70912-5. PMID 14381401.
=== Relapsing-remitting MS === Medications are modestly effective at decreasing the number of attacks in relapsing-remitting multiple sclerosis and in reducing the accumulation of brain lesions, which is measured using gadolinium-enhanced magnetic resonance imaging (MRI). Interferons reduce relapses by approximately 30% and their safe profile make them the first-line treatments. Nevertheless, not all the patients are responsive to these therapies. It is known that 30% of MS patients are non-responsive to Beta interferon. They can be classified in genetic, pharmacological and pathogenetic non-responders. One of the factors related to non-respondance is the presence of high levels of interferon beta neutralizing antibodies. Interferon therapy, and specially interferon beta 1b, induces the production of neutralizing antibodies, usually in the second 6 months of treatment, in 5 to 30% of treated patients. Moreover, a subset of RRMS patients with specially active MS, sometimes called "rapidly worsening MS" are normally non-responders to interferon beta 1a. While more studies of the long-term effects of the drugs are needed, existing data on the effects of interferons indicate that early-initiated long-term therapy is safe and it is related to better outcomes.
Sources: en.wikipedia.org
Also unlike irreversible μ-opioid receptor antagonists like β-funaltrexamine and β-chlornaltrexamine, methocinnamox lacks κ-opioid receptor agonism and is more selective for the μ-opioid receptor in its actions. Methocinnamox has been found to bind to two distinct sites on the μ-opioid receptor. It binds to the orthosteric site as a pseudo-irreversible and non-competitive antagonist, thereby directly blocking opioid binding. In addition, methocinnamox has been found to bind to and act as an antagonist of an unknown allosteric site on the μ-opioid receptor with lower affinity that modulates the affinity and/or intrinsic activity of orthosteric μ-opioid receptor agonists. The μ-opioid receptor antagonism of methocinnamox is non-competitive and insurmountable by μ-opioid receptor agonists like morphine and fentanyl. It has been found to completely block the effects of morphine at morphine doses of up to 1,000 mg/kg in animals, with the dose–response curve of morphine being shifted rightward by up to 100-fold. Doses of morphine of 1,000 mg/kg are normally often fatal. The insurmountability of methocinnamox's μ-opioid receptor antagonism is in contrast to that with competitive μ-opioid receptor antagonists like naloxone and naltrexone, which can be overcome with higher doses of μ-opioid receptor agonists. In contrast to the μ-opioid receptor, the antagonism of the κ- and δ-opioid receptors by methocinnamox is competitive and reversible. Moreover, methocinnamox shows a short duration in the body.
=== Commercialization === Elbasvir/grazoprevir was FDA approved in the United States, and has been approved for use in the European Union, Canada, Japan, Australia, Saudi Arabia, Israel, and Switzerland. Zepatier is one of a few non-interferon therapies that are market-available. Competing treatments include Gilead's Harvoni (sofosbuvir and ledipasvir) and AbbVie's Viekira Pak (ombitasvir, paritaprevir, and ritonavir). Sale projections for Zepatier are $636 million in 2016 and rising to $1.5 billion by 2020. With Merck's release of Zepatier early in 2016, they saw large bumps in share prices in quarters 1 and 2, but are expected to drop down a bit. Zepatier does not have as strong a market hold as other competitive HCV treatments.
β-Naltrexamine, or 6β-naltrexamine, is an opioid receptor antagonist related to naltrexol and naltrexone. It has served as a parent pharmacophore for irreversible antagonists of the μ-opioid receptor (MOR) such as β-chlornaltrexamine (β-CNA) and β-funaltrexamine (β-FNA). Naltrexamine itself is a neutral antagonist of the MOR and the δ-opioid receptor (DOR) with similarly high affinity for both receptors.
Various theories exist as to whether people who sustain carotid and vertebral artery dissection, even if they do not have a connective tissue disorder, have an underlying vulnerability. Biopsy samples of skin and other arteries has indicated that this might be a possibility, but no genetic defect in collagen or elastin genes has been convincingly proven. Other studies have indicated inflammation of the blood vessels, as measured by highly sensitive C-reactive protein (hsCRP, a marker of inflammation) in the blood. Once dissection has occurred, two mechanisms contribute to the development of stroke symptoms. Firstly, the flow through the blood vessel may be disrupted due to the accumulation of blood under the vessel wall, leading to ischemia (insufficient blood supply). Secondly, irregularities in the vessel wall and turbulence increase the risk of thrombosis (the formation of blood clots) and embolism (migration) of these clots of the brain. From various lines of evidence, it appears that thrombosis and embolism is the predominant problem. Subarachnoid hemorrhage due to arterial rupture typically occurs if the dissection extends into the V4 section of the artery. This may be explained by the fact that the arterial wall is thinner and lacks a number of structural supports in this section.
Sources: en.wikipedia.org
==== Urquía Carreño expelled from the Supreme Council ==== On January 25, 2024, the High Chamber of the Scottish Rite voted unanimously to sanction Urquía Carreño, determining that the actions of the Grand Master were "punishable and intentional, producing a large-scale Masonic schism in the national territory, which endangers the proper functioning of the Supreme Council and the Treaty of Friendship and Mutual Recognition." Shortly afterward, the Supreme Council issued Decree 009/2024, in which they declared that Urquía Carreño was henceforth expulsed from the Scottish Rite, writing that his actions were: "a clear sign of betrayal by failing to take the oath and loyalty to the fundamental principles of this Supreme Council." In this decree, Viñas Alonso iterated that Mario Urquía never wanted to inform anyone about the scandal, but that he refused to take part in Mario Urquía's attempted coverup. This document was signed by José Ramón Viñas Alonso. The Supreme Council levied the charge that Urquía Carreño had consistently lied about the facts of the case, and had attempted to manipulate the narrative in a public manner, writing that Urquía Carreño: "has established a field and visceral attack against the Supreme Council to which he himself belongs...
=== Lifestyle and diet === Drinking enough water may help to keep skin hydrated, especially in individuals who are chronically dehydrated. A poor diet lacking vitamins can lead to skin problems, such as scurvy, pellagra, and numerous subclinical skin pathologies that have not been studied in detail. Lack of sleep has been shown to make conditions like atopic dermatitis, eczema and psoriasis worse, and these conditions have in turn been shown to reduce sleep quality.
In Chennai, Tamil Nadu CMDA authorities placed a seal on the massive warehouse spreading across 7 acres that had reportedly been built for one of the world's leading multinational retail giants, Wal-mart. Domestic retail players like Future Retail, Avenues Supermarket and Aditya Birla Fashion and Retail has been slowly growing, making entering the country more difficult for MNCs like Walmart and Carrefour. On 28 August 2019, Indian union cabinet approved proposals to ease local sourcing norms as applicable to SBRT.
=== Management === No agents of biological pest control are used against the lesser mealworm. The fungus Beauveria bassiana is an arthropod pathogen that may prove useful. Some protozoa and spider species are known natural predators. Control is usually attempted with carbaryl insecticide in the form of powder, liquid, and bait. Thiamethoxam and 9-Tricosene used in conjunction have been shown to be successful in poultry houses. Pyrethroids and boric acid are used. True outbreaks are often uncontrollable and some populations of the beetle have shown resistance to various compounds. Resistance is more common on farms that have been chemically treated for many years. Insecticides are not ideal because they contaminate the poultry and they are not effective on the pest when it burrows out of reach. Proper maintenance of poultry housing usually keeps the beetle under control, as it propagates in accumulated litter and droppings.
==== Genetically induced ==== Type 1 diabetes (T1D) is a multifactorial autoimmune disease with a strong genetic component. Although environmental factors also play a significant role, the genetic susceptibility to T1D is well established, with several genes and loci implicated in disease development. The most significant genetic contribution to T1D comes from the human leukocyte antigen (HLA) region on chromosome 6p21. The HLA class II genes, particularly HLA-DR and HLA-DQ, are the strongest genetic determinants of T1D risk. Specific combinations of alleles such as HLA-DR3-DQ2 and HLA-DR4-DQ8 have been associated with a higher risk of developing T1D. Individuals carrying both of these haplotypes (heterozygous DR3/DR4) are at an even greater risk. These HLA variants are thought to influence the immune system's ability to differentiate between self and non-self antigens, leading to the autoimmune destruction of pancreatic beta cells. Conversely, some HLA haplotypes, such as HLA-DR15-DQ6, are associated with protection against T1D, suggesting that variations in these immune-related genes can either predispose or protect against the disease. In addition to HLA, multiple non-HLA genes have been implicated in T1D susceptibility. Genome-wide association studies (GWAS) have identified over 50 loci associated with an increased risk of T1D. Some of the most notable genes include:
Sources: en.wikipedia.org
Its legal status depends on the country and intended use. It is not an approved medicine in major jurisdictions. In sport, it is prohibited by anti-doping rules.
Laboratories typically use LC-MS/MS to detect SR9009 and related compounds in urine or blood. The method is sensitive but depends on sample collection timing. Confirmatory analysis follows quality-control procedures.
Solid material is generally kept cold, dry, and protected from light. Solutions are often stored in sealed containers at low temperature. Stability beyond recommended periods is not well documented.
Liquid chromatography–mass spectrometry is common for identity and purity checks. High-performance liquid chromatography with ultraviolet detection can also be used. Both methods require a suitable reference standard.